Risankizumab in Severe Asthma — A Phase 2a, Placebo-Controlled Trial

Although interleukin-23 has been implicated in the pathogenesis of asthma, in this randomized, controlled trial involving adults with severe asthma, inhibition of interleukin-23 signaling with the monoclonal antibody risankizumab resulted in worse asthma outcomes than placebo.

Saved in:
Bibliographic Details
Published in:The New England journal of medicine Vol. 385; no. 18; pp. 1669 - 1679
Main Authors: Brightling, Christopher E, Nair, Parameswaran, Cousins, David J, Louis, Renaud, Singh, Dave
Format: Journal Article
Language:English
Published: Boston Massachusetts Medical Society 28.10.2021
Massachussetts Medical Society
Subjects:
Adult
Aged
Allergy
Anti-Asthmatic Agents
Anti-Asthmatic Agents/adverse effects
Anti-Asthmatic Agents/therapeutic use
Antibodies, Monoclonal
Antibodies, Monoclonal/adverse effects
Antibodies, Monoclonal/therapeutic use
Asthma
Asthma/drug therapy
Bronchoscopy
Cell activation
Clinical trials
Critical Care
Cytokines
Cytotoxicity
Disease control
Disease Progression
Double-Blind Method
Double-blind studies
Female
Forced Expiratory Volume
Forced Expiratory Volume/drug effects
Gene expression
General & internal medicine
General Medicine
Glucocorticoids
Glucocorticoids/therapeutic use
Human health sciences
Humans
Immunology
Inflammation
Interleukin 23
Interleukin-23 Subunit p19
Interleukin-23 Subunit p19/antagonists & inhibitors
Lymphocytes T
Male
Medicine (all)
Middle Aged
Monoclonal antibodies
Médecine générale & interne
Natural killer cells
Neutrophils
Patients
Placebos
Pulmonary
Respiratory tract
Respiratory tract diseases
risankizumab
Safety
Sciences de la santé humaine
Sputum
Statistical analysis
Transcription activation
Transcription factors
Treatment Failure
ISSN:0028-4793, 1533-4406, 1533-4406
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:Although interleukin-23 has been implicated in the pathogenesis of asthma, in this randomized, controlled trial involving adults with severe asthma, inhibition of interleukin-23 signaling with the monoclonal antibody risankizumab resulted in worse asthma outcomes than placebo.
Bibliography:ObjectType-Article-1
SourceType-Scholarly Journals-1
ObjectType-Feature-2
content type line 14
ObjectType-Article-2
ObjectType-Feature-1
content type line 23
ObjectType-Undefined-3
scopus-id:2-s2.0-85118445608
ISSN:0028-4793
1533-4406
1533-4406
DOI:10.1056/NEJMoa2030880